Chlorambucil, a cornerstone alkylating agent in oncology and hematology, is critical for treating chronic lymphocytic leukemia (CLL), lymphomas, and autoimmune disorders. As global demand surges, suppliers must identify and engage high-potential buyers to capitalize on this $150 million market (projected to grow at 4.2% CAGR through 2033) . This guide reveals top buyers, regional dynamics, and proven strategies to dominate the Chlorambucil supply chain. ​1. Key Global Buyers by Region​ ​North America​ ​Europe​ ​Asia-Pacific​ ​Latin America & Africa​ ​2. Top Importers & Distributors​ ​Pharmaceutical Leaders​ Company Region Focus Area ​Teva Pharmaceuticals​ Israel/Europe Generic formulations ​Sandoz​ Switzerland Biosimilars and oncology ​Torrent Pharmaceuticals​ India Cost-effective CLL treatments ​Specialized Distributors​ ​3. Emerging Trends…